查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年阿片類藥物引起的便秘治療的全球市場
市場調查報告書
商品編碼
1140766

2022-2029 年阿片類藥物引起的便秘治療的全球市場

Global Opioid Induced Constipation Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），阿片類藥物引起的便秘治療的市場規模預計將以 4.4% 的複合年增長率增長。

阿片類鎮痛劑適用於患有急性和慢性非癌症疼痛的患者。阿片類藥物引起的便秘 (OIC) 是一種與長期使用阿片類藥物相關的繼發性疾病。大約 40% 至 80% 服用阿片類鎮痛藥的患者可能會出現 OIC。這些藥物之所以有效，是因為它們通過與整個神經系統的受體結合來阻斷疼痛信號。這些受體也存在於腸道中。

市場動態

全球阿片類藥物引起的便秘治療市場的增長歸因於 OIC 患者群的擴大，這是由於阿片類藥物在慢性疼痛治療□□中的使用增加所致。對 OIC 的安全有效治療的需求也日益增加。

慢性特發性疼痛患病率的增加以及有效 OIC 療法的增加將推動市場增長。

患者使用嗎啡、氫嗎啡酮和可待因等阿片類鎮痛劑作為非癌性慢性疼痛的處方，嚴重影響消化系統，導致對 OIC 藥物的大量需求。例如，根據疾病控制和預防中心 2021 年 11 月的數據，2019 年 OIC 處方數量增加到 153,260,450 份，到 2020 年增加到 142,816,781 份。因此，阿片類藥物使用者數量的增加將需要有效的藥物治療 OIC 疾病，這可能會在預測期內推動阿片類藥物引起的便秘市場。預計人口老齡化將對市場產生重大影響，因為 65 歲及以上的人更容易患慢性病。

根據 2021 年世界衛生組織事實，2015 年至 2050 年間，世界 60 歲以上人口的比例預計將翻一番，從 12% 增加到 22%。此外，根據世界衛生組織的數據，到 2030 年，地球上六分之一的人將超過 60 歲。預計 60 歲及以上人口將從 2020 年的 10 億增長到 2050 年的 14 億。到 2050 年，世界 60 歲以上的人口將翻一番，達到 21 億。從 2020 年到 2050 年，80 歲及以上的人口數量預計將增加兩倍，達到 4.26 億。因此，阿片類鎮痛劑處方的增加，以及發達國家老年人口的增加，將在預測期內推動市場增長。

患者對 OIC 缺乏認識是市場增長的障礙

但是，對於將 OIC 視為一種綜合徵並更喜歡普通瀉藥的患者缺乏認識，以及開發下一代止痛藥替代阿片類藥物的研究努力可能會阻礙市場增長。.

COVID-19 影響分析

COVID-19 影響了全球藥品供應鏈，並對阿片類藥物引起的便秘治療市場產生了積極影響。大劑量和長期使用阿片類藥物會損害免疫系統功能並使 COVID-19 疾病的病程複雜化。在 COVID-19 的不同階段，抑制某些免疫反應的潛力可能對藥物的預防、臨床支持和治療使用很重要。

細分分析

預計 mu 阿片受體拮抗劑細分市場在預測期內（2022-2029 年）將以最快的複合年增長率增長。

預計 Mu 阿片受體拮抗劑將在預測期內佔據很大的收入份額。這種主導地位歸因於主要參與者推出了適用於不同 OIC 症狀的不同類型的產品，以及該領域研究活動的增加。

市場上現成的用於 OIC 適應症的藥物包括甲基納曲酮 (Relistor)、Naldemedine (Symproic)、Naloxegol (Movantik) 和 Alvimopan (Entereg)。甲基納曲酮被研究並批准用於晚期癌症疼痛和其他疾病的患者，而 Alvimopan 和 Naloxegol 則用於非癌症患者。因此，預計 mu 阿片受體拮抗劑的可用性增加將推動預測期內的細分市場增長。

此外，2021 年 2 月，RedHill Biopharma Ltd. 與 Cosmo Pharmaceuticals NV 合作，與 Movantik（一種 fosi-阿片受體拮抗劑）合作，目前是非結核病肺 (NTM) 的單藥一線口服給藥。簽訂了生產兩種先導產品 RHB-204 的協議，該產品正處於美國第三階段試驗中，作為一種治療方法。這些因素正在推動預測期內的市場增長。

區域分析

北美在全球阿片類藥物引起的便秘治療市場中佔有最大的市場份額

預計北美將在整個預測期內主導阿片類藥物引起的便秘市場。這一優勢歸因於美國老年患者中各種胃腸道疾病的患病率不斷增加，以及加拿大最近阿片類藥物的消費量激增。根據 2020 年疾病控制和預防中心的數據，在美國，2020 年阿片類藥物的總體配藥率為每 100 人 43.3 個處方。因此，美國 OIC 處方數量的增加將在預測期內啟動市場。

此外，根據 2020 年 6 月發表在《未來醫學》(Future Medicine) 上的 Naldemedine 用於治療患有慢性非癌性疼痛的成人阿片類藥物引起的便秘的研究，Naldemedine 用於治療患有慢性非癌性疼痛的成人阿片類藥物引起的便秘。似乎是治療性便秘的有效且安全的一線治療方法。因此，預計該國增加產品開發和多項臨床試驗將推動該地區的市場。

競爭格局

阿片類藥物引起的便秘治療市場與本地和全球公司競爭適度。為市場增長做出貢獻的主要參與者包括阿斯利康 (AstraZeneca) plc、Mallinckrodt Pharmaceuticals、Bausch Health (Salix Pharmaceuticals)、默克公司、Shionogi &Co Ltd、葛蘭素史克 (Theravance Biopharma Inc)、武田製藥、諾華製藥 (Sandoz)，包括 RedHill Biopharma、輝瑞, Inc. 等。主要參與者採取了多種增長戰略，例如產品發布、收購和合作夥伴關係，這些戰略為全球阿片類藥物引起的便秘治療市場的增長做出了貢獻。例如，2022 年 1 月，BioGaia Pharma 報告了第一位患者參加了 2 期臨床試驗 (OIC-1)，該試驗評估了 BGP345A 用於治療阿片類藥物引起的便秘。

阿斯利康公司

概述

公司專注於心血管、腎臟/代謝、呼吸/免疫等腫瘤學和生物製藥領域處方藥的發現、開發和商業化。這些藥物是製造、銷售和銷售的。

產品組合

MOVANTIK：MOVANTIK 是一種處方藥，用於治療由稱為阿片類藥物的處方止痛藥引起的成人便秘，並伴有非活動性癌症引起的長期（慢性）疼痛。

本購入理由

  • 按藥物類別、給藥途徑、分銷渠道和地理區域可視化全球阿片類藥物誘發便秘治療市場的構成，突出關鍵商業資產和參與者。
  • 分析全球阿片類藥物引起的便秘治療市場的趨勢和聯合開發項目，以確定商機。
  • Excel 數據表包含全球阿片類藥物引起的便秘治療市場 4/5 級細分市場的數千個數據點。
  • 通過詳盡的定性訪談和深入的市場調查，獲得一份包含最相關分析的冷靜 PDF 報告。
  • 在 Excel 中為所有主要市場參與者的主要產品創建產品地圖

全球阿片類藥物誘發的便秘治療市場報告將提供對大約 40 多個市場數據表、45 多個圖表和大約 180-200 頁的範圍的訪問。

觀眾

  • 服務提供商/買方
  • 行業投資者/投資銀行家
  • 教育和研究機構
  • 調查員
  • 初創公司
  • 製造

內容

第 1 章阿片類藥物引起的便秘治療的全球市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章阿片類藥物引起的便秘治療的全球市場-市場定義和概述

第 3 章阿片類藥物引起的便秘治療的全球市場 - 執行摘要

  • 市場細分：按藥物類別
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章阿片類藥物引起的便秘治療的全球市場 - 市場動態

  • 市場影響因素
    • 驅動程序
      • 增加了有效的 OIC 療法的可用性
      • 由於慢性特發性疼痛的患病率上升，有效的 OIC 療法的可用性增加
    • 限制因素
      • 患者對 OIC 的認識不足
    • 商機
    • 影響分析

第 5 章阿片類藥物引起的便秘治療的全球市場 - 行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章阿片類藥物引起的便秘治療的全球市場 - COVID-19 分析

  • 對 COVID-19 市場的分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的定價動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章。全球阿片類藥物引起的便秘治療市場 - 按藥物類別

  • μ阿片受體拮抗劑
    • 甲基納曲酮
    • 納洛昔戈
    • 納爾多津
    • 其他
  • 氯離子通道活化劑
    • 魯比前列酮
    • 其他

第 8 章全球阿片類藥物引起的便秘治療市場 - 按管理途徑

  • 口語
  • 腸胃外

第 9 章。阿片類藥物引起的便秘治療的全球市場：按分銷渠道劃分

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 10 章全球阿片類藥物引起的便秘治療市場：按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章治療阿片類藥物引起的便秘的全球市場 - 競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章阿片類藥物引起的便秘治療的全球市場 - 公司簡介

  • 阿斯利康公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Mallinckrodt Pharmaceuticals
  • Bausch Heath（Salix Pharmaceuticals）
  • Merck & Co Inc
  • Shionogi & Co Ltd
  • GlaxoSmithKline（Theravance Biopharma Inc）
  • Takeda Pharmaceutical
  • Novartis AG（Sandoz）
  • Cubist Pharmaceuticals
  • Pfizer, Inc.

第13章 阿片類藥物引起的便秘治療的全球市場-DataM

簡介目錄
Product Code: DMPH1

Market Overview

Opioid-Induced Constipation Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.4% during the forecast period (2022-2029).

Opioid analgesics are prescribed to patients with acute and chronic non-cancer pain. Opioid-induced constipation (OIC) is a type of secondary illness associated with the prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesics may experience OIC. These medications are effective because they block pain signals by attaching to receptors throughout the nervous system. These receptors are also found in bowels.

Market Dynamics

The global opioid-induced constipation treatment market growth is driven by an expanding base of OIC sufferers as a result of the increased use of opioids in the treatment of chronic pain. Also, there is a vast unmet need in the market for highly-targeted, safe, and efficient therapeutic options for OIC management.

The rise in the availability of effective OIC drugs along with the growing prevalence of chronic idiopathic pains will drive the market growth

The patients use opioid analgesics such as morphine, hydromorphone, codeine, and others as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period. The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases.

According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the increasing use of opioid analgesic prescriptions along with the growing geriatric population in developed nations will drive the market growth in the forecast period.

Lack of awareness about OIC among the patients will hamper the growth of the market

However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, positively affecting the opioid-induced constipation treatment market. Opioid use at high doses and for long periods of time can impair immune system function, complicating the course of COVID-19 disease. In various stages of the COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications.

Segment Analysis

The mu-opioid receptor antagonists segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The Mu-opioid receptor antagonists are expected to account for a large revenue share over the forecast period. This dominance is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment.

A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg). Methylnaltrexone was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.

Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. These factors are driving the growth of the market in the forecast period.

Geographical Analysis

The North American region holds the largest market share of the global opioid-induced constipation treatment market

North America is expected to dominate the opioid-induced constipation market throughout the forecast period. Dominance is due to the growing prevalence of various GI disorders among geriatric patients in the United States and a steep rise in the consumption of opioids in Canada in recent years. According to the Center for Diseases Control and Prevention 2020, in the United States, the overall opioid dispensing rate in 2020 was 43.3 prescriptions per 100 people. Thus increasing number of OIC prescriptions in the United States boot the market over the forecast period.

Furthermore, according to the study titled Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancerous pain published in the Future Medicine In June 2020, Naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain. Thus, rising product development in the country and several clinical studies are expected to boost the market in the region.

Competitive Landscape

The opioid-induced constipation treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals), Merck & Co Inc, Shionogi & Co Ltd, GlaxoSmithKline (Theravance Biopharma Inc), Takeda Pharmaceutical, Novartis AG (Sandoz), RedHill Biopharma, Pfizer, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the opioid-induced constipation treatment market globally. For instance, in January 2022, BioGaia Pharma reported First Patient Enrolled in the Phase II Clinical Study Evaluating BGP345A for the treatment of opioid-induced constipation (OIC-1).

AstraZeneca PLC

Overview:

The company focuses on the discovery, development, and commercialization of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. These pharmaceutical products are then manufactured, marketed, and sold.

Product Portfolio:

MOVANTIK: MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.

Why Purchase the Report?

  • Visualize the composition of the global opioid-induced constipation treatment market segmentation by drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global opioid-induced constipation treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global opioid-induced constipation treatment market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global opioid-induced constipation treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Opioid-Induced Constipation Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Opioid-Induced Constipation Treatment Market -Market Definition and Overview

3. Global Opioid-Induced Constipation Treatment Market - Executive Summary

  • 3.1. Market Snippet By Drug Class
  • 3.2. Market snippet By Route of administration
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Opioid-Induced Constipation Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise in the availability of effective OIC drugs
      • 4.1.1.2. Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness about OIC among the patients
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Opioid-Induced Constipation Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Opioid-Induced Constipation Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Opioid-Induced Constipation Treatment Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Mu-Opioid Receptor Antagonists*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Methylnaltrexone
    • 7.2.4. Naloxegol
    • 7.2.5. Naldemedine
    • 7.2.6. Others
  • 7.3. Chloride Channel Activators
    • 7.3.1. Lubiprostone
    • 7.3.2. Others

8. Global Opioid-Induced Constipation Treatment Market - By Route of administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 8.1.2. Market Attractiveness Index, By Route of administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Parenteral

9. Global Opioid-Induced Constipation Treatment Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Other

10. Global Opioid Induced Constipation Treatment Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Opioid Induced Constipation Treatment Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Opioid Induced Constipation Treatment Market - Company Profiles

  • 12.1. AstraZeneca plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Mallinckrodt Pharmaceuticals
  • 12.3. Bausch Heath (Salix Pharmaceuticals )
  • 12.4. Merck & Co Inc
  • 12.5. Shionogi & Co Ltd
  • 12.6. GlaxoSmithKline (Theravance Biopharma Inc)
  • 12.7. Takeda Pharmaceutical
  • 12.8. Novartis AG (Sandoz)
  • 12.9. Cubist Pharmaceuticals
  • 12.10. Pfizer, Inc.

LIST NOT EXHAUSTIVE

13. Global Opioid Induced Constipation Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us